Cerus Corp Dossier
Qualitative Analysis
Business overview
Cerus Corporation is a global medical technology company focused on the field of blood transfusion safety. The company's core commercial offering is the proprietary INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens, including viruses, bacteria, and parasites, in donated blood components. The system utilizes single-use processing kits and specialized illuminator devices to treat platelets and plasma prior to transfusion. Cerus also markets the INTERCEPT Blood System for Cryoprecipitation, which produces Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) to treat and control bleeding. The company operates in a single business segment: Blood Safety.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Driving adoption and scaling production of the INTERCEPT Fibrinogen Complex (IFC) in the U.S. market, transitioning from finished therapeutic sales to kit-based manufacturing.
Expected impact: Expected to generate full-year 2026 IFC revenue of $22 million to $24 million, representing a significant growth driver for the overall product portfolio.
Broadening the market presence of the INTERCEPT platelet and plasma systems internationally, particularly in Europe and China, supported by new supply agreements.
Expected impact: Secures long-term recurring consumable kit revenue and increases global standard of care adoption.
Refinancing existing debt by closing a new credit facility of up to $110 million with MidCap Financial, consisting of a 5-year term loan and an asset-backed revolving loan.
Expected impact: Expected to reduce annual cash interest expense by up to $3.5 million, extend debt maturities, and improve financial flexibility.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
A new four-year supply agreement covering the INTERCEPT Blood System for platelets and plasma, as well as the next-generation INT200 device, across continental France and its overseas territories.
Terms: Specific financial terms were not disclosed; covers EFS's distribution of approximately 330,000 platelet units annually.
An extended supply and manufacturing agreement (the '2025 Agreement') running from January 1, 2025, through December 31, 2027, ensuring supply chain stability for key components (platelet wafers and plasma disks).
Terms: Secures unit pricing for the first two years, transitioning to a volume-based structure thereafter; specific pricing terms were not disclosed.